Get started
Author

Viacheslav A Chubenko

Observed names: V A Chubenko, V. A. Chubenko, V. Chubenko, V. F. Chubenko, V.A. Chubenko, V.A. Chubenko () Chubenko, V.  A. Chubenko, V.   A. Chubenko, Viacheslav A. Chubenko, Viacheslav Chubenko, В. А. Чубенко
ORCID: 0000-0001-6644-6687
Observed ORCID: 0000-0001-6644-6687
OpenAlex ID: A5025269387
Tumor acidity: From hallmark of cancer to target of treatment
2022 · Alexey Bogdanov, Andrey Bogdanov, et al. · Frontiers in Oncology · 190
PDF
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
2021 · Natalya V. Mazurina, Elena V. Artamonova, et al. · Journal of Modern Oncology · 11
PDF
Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer
2020 · Viacheslav Chubenko, Gamzat Inusilaev, et al. · BMJ Case Reports · 8
Real world efficacy of immunotherapy in nonsmall cell lung cancer
2020 · F. V. Moiseenko, N. M. Volkov, et al. · Malignant tumours · 4
PDF
Toxicity and efficacy of gemcitabine plus nab-paclitaxel (paclitaxel + albumin) in a Russian patient population: results of a multicenter retrospective study
2019 · I. A. Pokataev, M. A. Lyadova, et al. · Malignant tumours · 4
PDF
Virus-associated Tumors in Point of View of the Medical Oncologist: From Epidemiology to Treatment
2018 · V.A. Chubenko · Practical oncology · 4
PDF
Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study.
2024 · Viacheslav Chubenko, Olga Baklanova, et al. · Journal of Clinical Oncology · 3
PDF
First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia
2022 · D. I. Yudin, K. K. Laktionov, et al. · Meditsinskiy sovet = Medical Council · 3
PDF
Metronomic chemotherapy: efficacy in real clinical practice
2019 · V.A. Chubenko, L.A. Zagorskaya, et al. · Practical oncology · 3
PDF
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
2019 · Vera A Gorbunova, Irina V Kolyadina, et al. · Journal of Modern Oncology · 3
2016: advances in medical oncology
2017 · V.A. Chubenko · Practical oncology · 3
PDF
450P Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study
2024 · H. Sun, V. Moiseyenko, et al. · Annals of Oncology · 2
PDF
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study
2024 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology · 2
PDF
Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
2023 · A. A. Rumyantsev, A. E. Protasova, et al. · Tumors of female reproductive system · 2
PDF
Place of durvalumab in the treatment of biliary tract cancer: A review
2023 · Valeriy V. Breder, Evgenii V. Ledin, et al. · Journal of Modern Oncology · 2
PDF
Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
2021 · M.   Yu. Fedyanin, F.   V. Moiseenko, et al. · Surgery and Oncology · 2
PDF
Prospective II phase study on the evaluation of the efficacy of monotherapy with cetuximab as the first-line treatment for patients with metastatic colorectal cancer with wild-type KRas, NRas, and BRAF genes
2018 · V.M. Moiseenko () Moiseenko, F.V. Moiseenko ( Moiseenko, et al. · Фарматека · 2
Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study
2025 · I. V. Tsimafeyeu, O. V. Baklanova, et al. · Malignant tumours · 1
PDF
Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
2024 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 1
PDF
The third-line therapy for patients with metastatic colorectal cancer: regorafenib or repeated administration of drugs? A review
2022 · Ivan V. Rykov, Viacheslav A. Chubenko · Journal of Modern Oncology · 1
PDF
Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study
2022 · M.   Yu. Fedyanin, L.  Yu. Vladimirova, et al. · Surgery and Oncology · 1
PDF
Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
2020 · M. Yu. Fedyanin, F. V. Moiseenko, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
Long-term survival rates in cancer patients achieved with metronomic chemotherapy (cyclophosphamide and methotrexate).
2020 · Viacheslav Chubenko, Ludmila Zagorskaya, et al. · Journal of Clinical Oncology · 1
Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis
2019 · M. Fedyanin, D. Chekini, et al. · Annals of Oncology · 1
PDF
Toxicity and efficacy of FOLFIRI regimen and aflibercept combination in metastatic colorectal cancer: first results of a Russian multicenter retrospective study
2019 · M. Yu. Fedyanin, L. Yu. Vladimirova, et al. · Malignant tumours · 1
PDF
Works count: 66
Citation count: 260
H-index: 4
I10-index: 2
Year
Topic
Type